The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics
BT8009-100: A phase I/II study of novel bicyclic peptide and MMAE conjugate BT8009 in patients (pts) with advanced malignancies associated with nectin-4 expression, including urothelial cancer (UC).
 
Capucine Baldini
Consulting or Advisory Role - Bicycle Therapeutics; Janssen Oncology; Rising Tide Foundation
Research Funding - Foundation BMS (Inst)
Expert Testimony - Abbvie; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Amgen; MSD Oncology; Roche/Genentech
 
Vincent Goldschmidt
Research Funding - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Inca Pharma; Janssen-Cilag; Merck; Pfizer
(OPTIONAL) Uncompensated Relationships - MedImmune; NH TherAGuiX
 
Irene Brana
Consulting or Advisory Role - Achilles Therapeutics; Boehringer Ingelheim; Cancer Expert Now; eTheRNA Immunotherapies; Merck Sharp & Dohme; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; MSD; Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); GlaxoSmithKline (Inst); Gliknik (Inst); Immutep (Inst); ISA Pharmaceuticals (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nanobiotix (Inst); Northern Biologics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Shattuck Labs (Inst); VCN Biosciences (Inst)
Travel, Accommodations, Expenses - MSD Oncology
 
Bernard Doger
No Relationships to Disclose
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS
 
Sophie Cousin
No Relationships to Disclose
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Honoraria - Rocky Mountain Oncology Society
Consulting or Advisory Role - Abbvie (Inst); BostonGene (Inst); BostonGene (Inst); EMD Serono; Fujifilm (Inst); Inspirna (Inst); Jubilant Pharmaceuticals (Inst); Navire (Inst); Predicine (Inst); Regeneron (Inst); Silicon Therapeutics (Inst); Silicon Therapeutics (Inst); Teon Therapeutics (Inst); Turning Point Therapeutics (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ABL Bio (Inst); Accutar Biotech (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Artios (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioatla (Inst); BioInvent (Inst); Biothera (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Erasca, Inc (Inst); Exelixis (Inst); Freenome (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immunitas (Inst); Immunogen/MacroGenics (Inst); Incyte (Inst); Jacobio (Inst); Jazz Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Jubilant Pharmaceuticals (Inst); Kolltan Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Metabomed (Inst); Millennium (Inst); Mirati Therapeutics (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); Navire (Inst); NiKang Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Oncorus (Inst); Poseida (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyramid Biosciences (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Silicon Therapeutics (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tallac Therapeutics (Inst); Tarveda Therapeutics (Inst); TeneoBio (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst); Zhuhai Yufan Biotechnologies (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute; Synthorx/Sanofi
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Catalym; Clovis Oncology; GlaxoSmithKline; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Gilead Sciences; Ipsen; Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Pfizer; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)
 
Oscar Reig
Honoraria - Bristol-Myers Squibb; Ipsen; Pfizer
Consulting or Advisory Role - Eisai
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Pfizer; Sanofi
Travel, Accommodations, Expenses - Ipsen
 
Louise Carter
Consulting or Advisory Role - Athenex; Bicycle Therapeutics; Boehringer Ingelheim
Research Funding - ADC Therapeutics (Inst); Athenex (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); CellCentric (Inst); CytomX Therapeutics (Inst); Lilly (Inst); Lupin Pharmaceuticals (Inst); Merck Serono (Inst); Repare Therapeutics (Inst); Sierra Oncology (Inst); Takeda (Inst)
 
Elisa Fontana
Employment - HCA/Sarah Cannon
Consulting or Advisory Role - Astellas Pharma (I); Bristol-Myers Squibb (I); Celgene (I); SERVIER (I)
Research Funding - Amgen (Inst); Artios (Inst); Basilea (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech SE (Inst); Crescendo Biologics (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HUTCHMED (Inst); Jiangsu Hengrui Medicine (Inst); Mereo Biopharma (Inst); Merus (Inst); Nurix (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Roche (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Turning Point Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent No: 1716712.3 pending (I)
Travel, Accommodations, Expenses - Bristol-Myers Squibb (I); Caris Life Sciences; Repare Therapeutics; Sapience Therapeutics; Seagen; SERVIER (I)
Other Relationship - European Organisation for Research and Treatment of Cancer (EORTC)
 
Loic Verlingue
Leadership - Resolved
Consulting or Advisory Role - Adaptherapy
Research Funding - Bristol-Myers Squibb
 
Sebastien Hazard
No Relationships to Disclose
 
Amy Dickson
Employment - Bicycle Therapeutics
 
Cong Xu
Stock and Other Ownership Interests - Bicycle Therapeutics; Vertex
 
Hongmei Xu
Employment - Bicycle Therapeutics; Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics
Travel, Accommodations, Expenses - Bicycle Therapeutics
 
Rajiv Sharma
Employment - Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics; Roche
 
Dominic Smethurst
Employment - Bicycle Therapeutics
Leadership - Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics
 
Meredith McKean
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Castle Biosciences (Inst); Eisai (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
Research Funding - AADi (Inst); Accutar Biotech (Inst); Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); Astellas Pharma (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); OncoC4 (Inst); Oncorus (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Poseida (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Takeda (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)